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time, choice of validated patient reported outcome measures
(PRO) to assess and monitor ED, and opinion on how ED is
currently viewed. RESULTS: A total of 1658 congress delegates
participated in the study, of which 1590 met the inclusion crite-
ria. Sixty-one percent of the respondents prescribed a PDE5i as
the ﬁrst course of action when seeing an ED patient. Assessment
of contraindications or cardiovascular risk factors, physical
examination, blood pressure measurement, and laboratory tests
were rarely conducted as a ﬁrst course of action (1–3%, depend-
ing on the assessment/test). The most popular means of assessing
and monitoring ED status was via patient interview (68%), as
opposed to the use of validated PRO measures. Seventy-six
percent of respondents agreed that the large number of men
accessing ED medicines through uncontrolled sources repre-
sented a true medical issue and 81% agreed that actions to
reduce health risks associated with such uncontrolled access
to PDE5i were essential. CONCLUSIONS: While the EAU
guidelines recommend a diagnostic workup prior to prescribing
PDE5is, this study demonstrates that a majority of participating
respondents initiate PDE5i treatment in an ED patient initially
after a simple patient interview with no prior physical examina-
tion or diagnostic testing.
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OBJECTIVES: Dalbavancin is a new, once weekly, intravenous,
glycopeptide antibacterial. In phase III trial, dalbavancin demon-
strated comparable efﬁcacy versus linezolid in complicated skin
and soft tissue infections (cSSTIs). Teicoplanin is a key antimicro-
bial comparator in Europe, therefore an indirect comparison
based on available published efﬁcacy was performed in “all”
Staphylococcus aureus (SA) patients. A Bayesian meta-analysis
was conducted to compare success rates of antibacterials versus
teicoplanin in cSSTIs due to SA. METHODS: Medline, Embase,
andCochrane databaseswere searched to identify clinical trials on
dalbavancin, daptomycin, linezolid, telavancin, teicoplanin, tige-
cycline, and vancomycin in cSSTIs. Two independent reviewers
completed data extraction, study quality, and heterogeneity
assessment. Pooled efﬁcacy estimates were generated based on
clinical and microbiological success rates for the all SA cSSTI
patients. A random effects model was used with outcome pre-
dicted by medication and confounders of success deﬁnition,
dosing, age and gender. The impact of base case confounders, ﬁxed
vs random effects models and doses was investigated in sensitivity
analyses. RESULTS: Out of 36 articles, reporting on 11 trials,
6 treatments and 17 treatment arms (n = 955) were included.
Pooled success rate for teicoplanin was 88.6% (71.7;97.2) and
differences versus comparators for the base case analysis are:
vancomycin -9.4% (-47.1;15.5), linezolid +0.4% (-12.9;17.6),
tigecycline -6% (-9.7;17.7), dalbavancin +0.5% (-12.9;16.8),
and telavancin -5% (-43.7;21.5). Success rates for dalbavancin
and linezolid were numerically higher versus teicoplanin,
although differences were not signiﬁcant. These ﬁndings were
consistent in a variety of sensitivity analyses. CONCLUSIONS:
Dalbavancin demonstrated high microbiological success rates,
comparable to teicoplanin and other antimicrobials in SA cSSTI.
These data are consistent with the results of the phase III study
versus linezolid. In the context of the limited numbers of patients
available for some agents and the indirect nature of the compari-
son; further analyses are needed in this populations.
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OBJECTIVES: To compare success rates of newer antimicrobial
agents to vancomycin for treatment of MRSA cSSTIs using a
Bayesian meta-analysis. METHODS: A systematic literature
review was conducted of Medline, Embase, and Cochrane data-
bases to identify clinical trials on dalbavancin, daptomycin, lin-
ezolid, telavancin, teicoplanin, tigecycline, and vancomycin in
cSSTIs. Data extraction, study quality, and heterogeneity assess-
ments were completed by two independent reviewers. Pooled
efﬁcacy estimates were generated based on clinical and micro-
biological success rates for the MRSA-subgroups in the cSSTI
clinical trials using a Bayesian approach. The base case used a
random effects model with outcome predicted by medication and
confounders of success deﬁnition, dosing, age and gender. Sensi-
tivity analyses included testing impact of base case confounders,
ﬁxed vs random effects models, article quality, and difference in
success deﬁnition. RESULTS: Of 35 initially identiﬁed studies, 14
trials on six treatments with 28 treatment arms (n = 1840) met
the inclusion criteria for the MRSA subpopulation and were
included in the analysis. No MRSA-speciﬁc data were reported
for teicoplanin, thus it was not included. MRSA-conﬁrmed cSSTI
pooled success rates and 95% credible intervals for the base case
analysis were: vancomycin 74.7% (64.1–83.5%), linezolid
84.4% (76.6–90.6%), daptomycin 78.1% (54.6–93.2%), tigecy-
cline 70.4% (48.0–87.6%), dalbavancin 87.7% (74.6–95.4%),
and telavancin 83.5% (73.6–90.8%). The estimated difference
with vancomycin was signiﬁcant for dalbavancin, linezolid and
telavancin. The ﬁnding of lower vancomycin efﬁcacy in MRSA
cSSTI was consistent in a variety of sensitivity analyses, indicat-
ing the results were robust. CONCLUSIONS: This meta-analysis
suggests higher success rates for the novel glycopeptides and
linezolid in the treatment of MRSA-conﬁrmed cSSTIs. The uncer-
tainty margins reﬂect the limited numbers of patients available
for some agents and the indirect nature of the treatment com-
parisons. Further evidence from randomized clinical trials is
needed to more deﬁnitively establish the value of the newer
antimicrobials in MRSA cSSTIs.
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OBJECTIVES: To forecast through computer simulation the
effectiveness of medical intervention strategies in reducing the
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expected number of cases of meningococcal meningitis in a devel-
oping country (Kenya). METHODS: We constructed a simula-
tion model of the spread of meningitis and the effects of
intervention strategies with data from peer-reviewed literature.
The effectiveness of each intervention strategy was measured in
terms of the expected annual number of cases of meningococcal
meningitis prevented, relative to a “do nothing” strategy. Each
person in a population of 10,000 was modeled daily as a distinct
entity with an array of personal and demographic attributes. This
approach captured the population heterogeneity and allowed
modeling person-to-person interactions. Modeling population
members as distinct entities also allowed us to direct intervention
strategies toward at-risk individuals. Simulations using 100 dif-
ferent seeds, representing unique starting years were performed.
Intervention strategies were: 1) vaccinating 6-year olds entering
school; 2) vaccinating persons ages three to ﬁfteen years (the
most at-risk population); and 3) providing chemoprophylaxis
(antibiotics for short term protection against invasive cases of the
disease) to family members of meningococcal meningitis patients.
Vaccination provides protection for a speciﬁed period of time
(2 years by default), while chemoprophylaxis is protecting only
during the course of the drug. A force-of-infection function rep-
resenting the probability that a person exposed to a carrier
becomes infected allows modeling of seasonal variation.
RESULTS: Average annual number of cases without treatment
was 29.54. Strategy 1 reduced expected annual cases by 4.91
(p < 0.01), strategy 2 by 16.91 (p < 0.01), and strategy 3 by 1.21
(NS). CONCLUSIONS: The strategy of vaccinating only six-
year-old children and the strategy of vaccinating persons ages
three to ﬁfteen years both signiﬁcantly reduced the number of
invasive cases. The strategy of giving chemoprophylaxis to family
members of meningococcal meningitis patients did not signiﬁ-
cantly reduce the number of invasive cases.
PIN4
A MARKOV MODELTO ESTIMATETHE IMPACT ON
MORBIDITY AND MORTALITY IN PATIENTS WITH CHRONIC
HEPATITIS C (CHC) AND NORMALTRANSAMINASES (ALT-N)
TREATED WITH PEGYLATED BITHERAPY
Deufﬁc-Burban S1, Moser A2, Cartier V2, Deltenre P3,
Canva-Delcambre V3, Dharancy S3, Louvet A3, Roudot-Thoraval F4,
Mathurin P3
1INSERM U795, Lille, France, 2Roche Pharma, Neuilly sur Seine
Cedex, France, 3CHRU de Lille, Lille Cedex, France, 4Hopital
Henri-Mondor, Creteil, France
OBJECTIVES: HCV patients with ALT-N have a slower pro-
gression to cirrhosis than patients with elevated transaminases
(ALT-E). The use and impact of treatment on HCV progression
are controversial in this population. We estimated the impact of
antiviral treatment on the morbidity and mortality in patients
with ALT-N, comparing with ALT-E, following different sce-
narios of treatment. METHODS: A Markov model of CHC
with a twenty-year time horizon (2006–2025) was adapted to
simulate ALT-N patients (30%) and ALT-E patients (70%)
separately. The model takes into account: 1) The faster ﬁbrosis
progression rates for higher age, males and ALT-E; 2) The
improvement of HCV screening and treatment; 3) The competi-
tive mortality. The model is calibrated on reported HCC mor-
tality (CepiDc). Antiviral treatment effects were incorporated
by estimating the likelihood of being screened for HCV (InVS),
of being treated (GERS) and of becoming sustained viral
responders (literature review). We assumed that patients with
ALT-N are treated 80% lower between 2002 and 2004 and
70% lower from 2005 than the ALT-E (HEPATYS). A sensitiv-
ity analysis has been assessed. RESULTS: The model showed
that the antiviral treatment reduced by 36,000 cirrhosis (35%),
23,100 cirrhosis complications (26%) and 18,000 deaths
(23%) on the total HCV population, including 3,000 cirrhosis
(20%), 1,200 complications (14%) and 1,000 deaths (13%) in
the ALT-N population, despite a probability to be treated 3 to
5 times lower in this population. Moreover, if ALT-N patients
are treated in the same proportions than ALT-E, morbidity and
mortality could be further reduced by 1,400 cirrhosis (12%),
600 complications (9%) and 500 deaths (8%). CONCLU-
SIONS: The treatment of CHC patients with ALT-N should
have a long-term impact on morbidity and mortality, less
important than in ALT-E patients. The sensitivity analysis
showed that the proportion of ALT-N is the parameter having
the most inﬂuence on the results.
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OBJECTIVES: To assess the impact of mass vaccination with
Priorix-Tetra™ (GlaxoSmithKline Biologicals’ MMRV; measles,
mumps, rubella, varicella) vaccine versus Priorix™ (GlaxoSmith-
Kline Biologicals’ MMR; measles, mumps, rubella) vaccine on
the epidemiology of varicella and zoster. Sustained high coverage
with MMRV is possible by replacing MMR. Vaccination can
cause an age shift in varicella incidence, and could conceivably
increase zoster incidence by removing the trigger for internal
boosting of immunity to zoster. METHODS: A dynamic trans-
mission model was developed, accounting for the natural history
of varicella and zoster, virus transmission, interactions between
varicella and zoster (boosting effects), and age-speciﬁc contact
rates. The model used peer-reviewed French data. Scenarios were
run to evaluate uncertainty in contact patterns within and
between age groups. RESULTS: Following the introduction of
MMRV, varicella incidence was signiﬁcantly reduced from
12,571 to 4,859/million person-years at the post-vaccination
equilibrium (after around 30 years). All evaluated contact pat-
terns predicted large decreases in disease incidence. Zoster inci-
dence increased slightly in the ﬁrst 20 years post-vaccination (e.g.
1860 to 1918/million-person-years in people aged >50 years).
This then declined as the vaccinated cohort aged, due to the
assumed lower viral reactivation rate with the vaccine. Before
vaccination, the highest incidence of varicella was in the 2–4 year
olds, but this shifted to the 5–11 year age group (pre-vaccination
incidence 2373 versus 3535/million person-years after MMRV).
Neither the short term increase in zoster cases nor the age shift to
5–11 year olds were projected to have a signiﬁcant impact on the
burden of the disease. By 80 years post-vaccination, the incidence
of zoster had decreased from 3242 to 1326/million person-years
and was still decreasing as the vaccinated cohort aged. CON-
CLUSIONS: Replacement of Priorix™ with Priorix-Tetra™
allows sustained mass vaccination against varicella which is pre-
dicted to signiﬁcantly reduce varicella, and eventually zoster,
incidence and disease burden.
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